Exact enlists Mayo Clinic for big, real-world Cologuard study

By LabPulse.com staff writers

October 14, 2019 -- Exact Sciences is working with the Mayo Clinic in Rochester, MN, on a 150,000-patient, long-term, real-world study -- dubbed Voyage -- of its Cologuard noninvasive test for colon cancer.

Cologuard tests stool for 10 DNA markers, as well as for blood. The Mayo Clinic will lead the prospective, observational study, which will enroll patients nationwide who have a clinical order for the test and will track the use of health services and outcomes -- including mortality -- over the course of seven years. Outcomes data from real-world settings can be useful for boosting uptake with providers and reimbursement with payors. In a statement, the company said the data will build the evidence base and support continued adoption of the product.

Cologuard was initially cleared in 2014 by the U.S. Food and Drug Administration (FDA) for people age 50 years and older. The approval was supported by a prospective validation study of 10,000 people. In September, the FDA expanded the clearance to include use in people 45 years and older who are at average risk for colon cancer.

Novigenix reports data for ColoxPlus blood test
Novigenix reported high sensitivity and specificity for its ColoxPlus next-generation sequencing blood test for early colon cancer detection in a study...
ESMO: Blood test predicts relapse risk in colon cancer
A blood test showed potential for predicting relapse in nonmetastatic colon cancer patients and for reducing unnecessary treatments in a large study reported...
FDA clears Exact's colorectal cancer screening for younger adults
The U.S. Food and Drug Administration (FDA) has approved Exact Sciences' noninvasive colorectal cancer screening test, Cologuard, for eligible average-risk...
Machine learning helps liquid biopsy detect cancer based on DNA
A new liquid biopsy blood test under development at Johns Hopkins University could detect up to seven types of cancer by using machine learning to help...
Aspirin doesn't improve sensitivity of colon cancer FIT
Giving a single dose of aspirin to individuals undergoing a fecal immunochemical test (FIT) does not improve the sensitivity of the test, according to...

Copyright © 2019 LabPulse.com

Last Updated np 10/14/2019 11:14:20 AM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email